India Pharma Outlook Team | Thursday, 26 February 2026
Dr Reddy’s Laboratories is gearing up to launch its generic semaglutide injection in India as early as March, according to sources familiar with the matter.
The Hyderabad-based drugmaker is preparing for a market entry soon after the patent on semaglutide expires, opening the door for lower-cost versions of the blockbuster diabetes and weight-loss therapy.
The company is expected to market the product under the brand name Obeda, though it has not officially announced the launch timeline. Semaglutide is the active ingredient behind Novo Nordisk’s widely known treatments for type 2 diabetes and obesity.
Also Read: Bridging Collaboration Gaps to Boost India's Pharma Discovery
With patent protection ending in India in March, several domestic drugmakers are lining up to introduce more affordable options, and Dr Reddy’s appears ready to move quickly.
Sources said the company aims to roll out around 12 million injectable pens in the first year. The generic semaglutide is likely to be priced significantly lower than the innovator brands, potentially up to 60% cheaper. A lower price could expand access for millions of patients dealing with diabetes and obesity in India, where demand for these therapies has surged.
Industry watchers see this launch as a major shift in the weight-loss and diabetes drug market. If executed as planned, Dr Reddy’s entry could intensify competition and drive prices down further, reshaping the treatment landscape in the months ahead.
